Management of COVID19: NICE guidelines updated May 2025
May 2025
The recommendation for nirmatrelvir plus ritonavir was updated. The recommendation made in March 2024 after a partial review of the guidance was based on a confidential price offered by the company to the NHS. In May 2025, the company set a new list price of £829. This was because NICE was considering if the recommendation needed to be reviewed due to the evolving COVID-19 landscape and emerging data from NHS England. Nirmatrelvir plus ritonavir is no longer cost effective for the groups evaluated in the partial review (people with diabetes, obesity or heart failure, or aged 70 years or over). So, these groups were removed from the recommendation.
Nirmatrelvir plus ritonavir remains cost effective for the highest-risk group, so this recommendation remains in place.
